Researchers investigated the value of the metabolic tumor response assessed with FDG-PET, compared with clinico-biological markers to predict pCR to neoadjuvant chemotherapy in women with triple-negative breast cancer.

READ FULL ARTICLE Curated publisher From clincancerres.aacrjournals.org